The TGA has approved Apellis Pharmaceuticals' SYFOVRE (pegcetacoplan) for the every-other-month treatment of adult patients with a form of age-related macular degeneration. …
TGA approves Apellis therapy for a form of age-related macular degeneration
January 28, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
President's nominee denies calling for seizure of pharmaceutical patents
January 30, 2025 - - Latest News -
GPs call on NSW Government to fund free Meningococcal B vaccine
January 30, 2025 - - Latest News -
New Zealand's Pharmac reconsiders proposed move to single oestradiol patch brand
January 30, 2025 - - Latest News -
QBiotics strengthens medical leadership with two senior appointments
January 28, 2025 - - Australian Biotech -
Chemist Warehouse reports strong sales and earnings growth with merger to progress
January 28, 2025 - - Latest News -
Trapped arguing for changes that won't make a meaningful difference
January 28, 2025 - - Latest News -
Medicines Australia wants progress on 'immediate impact' recommendations
January 28, 2025 - - Latest News